Skip to main navigation Skip to search Skip to main content

Non-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS

  • Domenico Luca Grieco
  • , Salvatore Maurizio Maggiore
  • , Oriol Roca
  • , Elena Spinelli
  • , Bhakti K. Patel
  • , Arnaud W. Thille
  • , Carmen Sílvia V. Barbas
  • , Marina Garcia De Acilu
  • , Salvatore Lucio Cutuli
  • , Filippo Bongiovanni
  • , Marcelo Amato
  • , Jean-Pierre Frat
  • , Tommaso Mauri
  • , John P. Kress
  • , Jordi Mancebo
  • , Massimo Antonelli
  • ASL02 Lanciano‐Vasto Chieti
  • Vall d'Hebron Research Institute
  • IRCCS Fondazione Ca'Granda – Ospedale Maggiore Policlinico - Milano
  • The University of Chicago
  • CHU de Poitiers
  • Universidade de São Paulo
  • Hematology, Hospital Santa Creu i Sant Pau

Research output: Contribution to journalArticle

Abstract

The role of non-invasive respiratory support (high-flow nasal oxygen and noninvasive ventilation) in the management of acute hypoxemic respiratory failure and acute respiratory distress syndrome is debated. The oxygenation improvement coupled with lung and diaphragm protection produced by non-invasive support may help to avoid endotracheal intubation, which prevents the complications of sedation and invasive mechanical ventilation. However, spontaneous breathing in patients with lung injury carries the risk that vigorous inspiratory effort, combined or not with mechanical increases in inspiratory airway pressure, produces high transpulmonary pressure swings and local lung overstretch. This ultimately results in additional lung damage (patient self-inflicted lung injury), so that patients intubated after a trial of noninvasive support are burdened by increased mortality. Reducing inspiratory effort by high-flow nasal oxygen or delivery of sustained positive end-expiratory pressure through the helmet interface may reduce these risks. In this physiology-to-bedside review, we provide an updated overview about the role of noninvasive respiratory support strategies as early treatment of hypoxemic respiratory failure in the intensive care unit. Noninvasive strategies appear safe and effective in mild-to-moderate hypoxemia (PaO2/FiO(2) > 150 mmHg), while they can yield delayed intubation with increased mortality in a significant proportion of moderate-to-severe (PaO2/FiO(2) <= 150 mmHg) cases. High-flow nasal oxygen and helmet noninvasive ventilation represent the most promising techniques for first-line treatment of severe patients. However, no conclusive evidence allows to recommend a single approach over the others in case of moderate-to-severe hypoxemia. During any treatment, strict physiological monitoring remains of paramount importance to promptly detect the need for endotracheal intubation and not delay protective ventilation.
Original languageEnglish
Pages (from-to)851-866
Number of pages16
JournalIntensive Care Medicine
Volume47
DOIs
Publication statusPublished - 2021

Keywords

  • Acute hypoxemic respiratory failure (AHRF)
  • Acute respiratory distress syndrome (ARDS)
  • Continuous positive airway pressure (CPAP)
  • High-flow nasal oxygen (H-FNO)
  • Inspiratory effort
  • Noninvasive ventilation (NIV)
  • Patient self-inflicted lung injury (P-SILI)
  • Pressure support ventilation (PSV)
  • Transpulmonary pressure

Fingerprint

Dive into the research topics of 'Non-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS'. Together they form a unique fingerprint.

Cite this